Data / Drug companies / Biocon Limited
Biocon Limited: 62 products in the FDA NDC directory, labeler code 65727
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Biocon Limited (labeler code 65727) lists 62 products in the FDA National Drug Code Directory. By type: 62 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on March 28, 2026.
The request: Watch Biocon Limited (FDA labeler code 65727): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 65727
- Products in commercial distribution
- 62
- Packages
- 63
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 1
- Earliest marketing start
- January 1, 2000
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 62 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 62 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 62 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Relugolix | 65727-111 | Powder | Bulk ingredients | March 28, 2026 |
| Trametinib dimethylsulfoxide | 65727-115 | Powder | Bulk ingredients | March 20, 2026 |
| Edoxaban tosylate monohydrate | 65727-113 | Powder | Bulk ingredients | February 27, 2026 |
| Eltrombopag olamine | 65727-098 | Powder | Bulk ingredients | November 29, 2025 |
| Tirzepatide | 65727-109 | Powder | Bulk ingredients | October 22, 2025 |
| Enzalutamide | 65727-110 | Powder | Bulk ingredients | August 28, 2025 |
| Posaconazole (form- 1) | 65727-107 | Powder | Bulk ingredients | April 1, 2025 |
| Nintedanib esylate | 65727-104 | Powder | Bulk ingredients | March 26, 2025 |
| Olaparib | 65727-103 | Powder | Bulk ingredients | March 25, 2025 |
| Ivacaftor | 65727-095 | Powder | Bulk ingredients | February 22, 2025 |
| Semaglutide | 65727-094 | Powder | Bulk ingredients | September 17, 2024 |
| Lurasidone hydrochloride | 65727-096 | Powder | Bulk ingredients | March 18, 2024 |
| Tacrolimus | 65727-101 | Powder | Bulk ingredients | March 12, 2024 |
| Orlistat pellets | 65727-093 | Powder | Bulk ingredients | March 1, 2024 |
| Dapagliflozin propane diol | 65727-092 | Powder | Bulk ingredients | March 1, 2024 |
| Lenalidomide hemihydrate | 65727-097 | Powder | Bulk ingredients | December 7, 2023 |
| Everolimus premix 2 % | 65727-086 | Powder | Bulk ingredients | November 7, 2023 |
| Cabozantinib-(s)-malate | 65727-091 | Powder | Bulk ingredients | July 24, 2023 |
| Glatiramer acetate | 65727-038 | Powder | Bulk ingredients | July 5, 2023 |
| Sitagliptin phosphate monohydrate | 65727-053 | Powder | Bulk ingredients | March 1, 2023 |
| Empagliflozin | 65727-085 | Powder | Bulk ingredients | December 1, 2021 |
| Sitagliptin hydrochloride | 65727-071 | Powder | Bulk ingredients | December 1, 2021 |
| Linagliptin | 65727-057 | Powder | Bulk ingredients | September 5, 2021 |
| Rivaroxaban | 65727-050 | Powder | Bulk ingredients | August 29, 2021 |
| Apixaban | 65727-081 | Powder | Bulk ingredients | August 27, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.